GlassScriptPhysician profile
Richard Scott Thomas
NPI 1265795660
$3,698.99
in general payments reported to CMS, 2019-2025
31 companies · $632 in 2025
The $632 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $298 · 2021: $390 · 2022: $291 · 2023: $905 · 2024: $913 · 2025: $632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,296 · Education: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,295.54 |
| Education | $154.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $997.95 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $595.79 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $197.51 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $179.43 | 2020-2025 | Tremfya, Simponi Aria, Simponi |
| E.R. Squibb & Sons, L.L.C. | $176.56 | 2022-2025 | Sotyktu |
| Sun Pharmaceutical Industries INC. | $131.04 | 2019-2023 | |
| Genzyme Corporation | $130.58 | 2022-2025 | |
| Dermavant Sciences, INC. | $110.86 | 2023-2024 | Vtama |
| Amgen INC. | $110.03 | 2019-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $106.97 | 2023-2025 | Zoryve |
| Ucb, INC. | $94.96 | 2021-2025 | Bimzelx |
| Prugen, INC. Pharmaceuticals | $90.84 | 2020 | |
| Biofrontera INC. | $90.42 | 2019-2021 | |
| Lilly USA, LLC | $88.52 | 2019-2025 | Olumiant, Taltz |
| Incyte Corporation | $76.94 | 2022-2024 | Opzelura |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $63.30 | 2023 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.53 | 2023 | Spevigo, Cyltezo |
| Pfizer INC. | $56.60 | 2019-2021 | |
| Galderma Laboratories, L.P. | $50.85 | 2024-2025 | Nemluvio |
| Strata Skin Sciences, INC. | $39.73 | 2023-2024 | Xtrac |
| Organogenesis INC. | $39.04 | 2021 | |
| Organon LLC | $38.77 | 2025 | Vtama |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $29.88 | 2019-2021 | |
| Mimedx Group, INC. | $24.94 | 2024 | |
| Acadia Pharmaceuticals INC | $24.57 | 2023 | Nuplazid |
| Celgene Corporation | $21.98 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $18.31 | 2019 | |
| Krystal Biotech INC | $15.08 | 2024 | Vyjuvek |
| Merck Sharp & Dohme LLC | $13.20 | 2019 | |
| Genentech USA, INC. | $12.69 | 2019 | |
| Allergan, INC. | $12.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.